Stocks
Arena Pharmaceuticals Financial Statements (ARNA) |
||||||||||
| Arena Pharmaceuticalssmart-lab.ru | % | 2020Q4 | 2021Q1 | 2021Q2 | 2021Q3 | 2021Q4 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 23.02.2021 | 05.05.2021 | 05.08.2021 | 04.11.2021 | 23.02.2022 | 23.02.2022 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.037 | 0.000 | 0.000 | 0.000 | 0.054 | 0.054 | |||
| Operating Income, bln rub | -135.3 | -132.0 | -144.4 | -194.5 | -154.6 | -625.5 | ||||
| EBITDA, bln rub | ? | -120.1 | -117.4 | -144.1 | -194.3 | -153.7 | -609.5 | |||
| Net profit, bln rub | ? | -122.2 | -118.4 | -146.1 | -196.3 | -156.6 | -617.4 | |||
| OCF, bln rub | ? | -106.4 | -120.0 | -93.8 | -117.7 | -120.5 | -452.0 | |||
| CAPEX, bln rub | ? | 0.136 | 0.097 | 0.205 | 70.2 | 0.533 | 71.0 | |||
| FCF, bln rub | ? | -106.5 | -120.1 | -94.0 | -187.8 | -121.0 | -523.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 135.3 | 132.0 | 144.4 | 124.5 | 153.5 | 554.3 | ||||
| Cost of production, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| R&D, bln rub | 100.4 | 102.5 | 112.5 | 94.2 | 110.3 | 419.5 | ||||
| Interest expenses, bln rub | 1.10 | 0.000 | 1.05 | 1.03 | 1.00 | 3.09 | ||||
| Assets, bln rub | 1 191 | 1 184 | 1 085 | 901.0 | 784.7 | 784.7 | ||||
| Net Assets, bln rub | ? | 1 080 | 1 086 | 971.1 | 800.7 | 673.2 | 673.2 | |||
| Debt, bln rub | 45.6 | 44.6 | 43.5 | 42.4 | 41.2 | 41.2 | ||||
| Cash, bln rub | 1 104 | 1 089 | 971.5 | 771.7 | 550.5 | 550.5 | ||||
| Net debt, bln rub | -1 058 | -1 044 | -928.0 | -729.3 | -509.3 | -509.3 | ||||
| Ordinary share price, rub | 76.8 | 69.4 | 68.2 | 59.6 | 92.9 | 94.0 | ||||
| Number of ordinary shares, mln | 58.3 | 59.8 | 60.8 | 61.1 | 61.4 | 61.4 | ||||
| Market cap, bln rub | 4 478 | 4 148 | 4 146 | 3 641 | 5 704 | 5 767 | ||||
| EV, bln rub | ? | 3 420 | 3 104 | 3 218 | 2 912 | 5 195 | 5 258 | |||
| Book value, bln rub | 1 080 | 1 086 | 971 | 801 | 673 | 673 | ||||
| EPS, rub | ? | -2.10 | -1.98 | -2.40 | -3.21 | -2.55 | -10.1 | |||
| FCF/share, rub | -1.83 | -2.01 | -1.55 | -3.07 | -1.97 | -8.52 | ||||
| BV/share, rub | 18.5 | 18.2 | 16.0 | 13.1 | 11.0 | 11.0 | ||||
| EBITDA margin, % | ? | -324 611% | -284 539% | -1 128 657% | ||||||
| Net margin, % | ? | -330 165% | -290 026% | -1 143 404% | ||||||
| FCF yield, % | ? | -7.90% | -9.15% | -9.54% | -14.0% | -9.17% | -9.07% | |||
| ROE, % | ? | -37.5% | -38.9% | -49.9% | -72.8% | -91.7% | -91.7% | |||
| ROA, % | ? | -34.0% | -35.7% | -44.6% | -64.7% | -78.7% | -78.7% | |||
| P/E | ? | -11.1 | -9.81 | -8.56 | -6.25 | -9.24 | -9.34 | |||
| P/FCF | -12.7 | -10.9 | -10.5 | -7.16 | -10.9 | -11.0 | ||||
| P/S | ? | 14 038 | 72 774 | 72 730 | 98 402 | 105 638 | 106 798 | |||
| P/BV | ? | 4.14 | 3.82 | 4.27 | 4.55 | 8.47 | 8.57 | |||
| EV/EBITDA | ? | -8.42 | -7.39 | -6.75 | -5.06 | -8.52 | -8.63 | |||
| Debt/EBITDA | 2.61 | 2.49 | 1.95 | 1.27 | 0.84 | 0.84 | ||||
| R&D/CAPEX, % | 73 854% | 105 706% | 54 855% | 134.2% | 20 702% | 591.0% | ||||
| CAPEX/Revenue, % | 367.6% | 987.0% | 131 459% | |||||||
| Arena Pharmaceuticals shareholders | ||||||||||
